Moderna, Inc. (NASDAQ:MRNA – Get Rating)’s stock price dropped 2.5% during trading on Tuesday after Morgan Stanley lowered their price target on the stock from $197.00 to $175.00. The stock traded as low as $135.39 and last traded at $135.73. Approximately 60,581 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 5,047,652 shares. The stock had previously closed at $139.25.
Several other research analysts have also recently issued reports on MRNA. SVB Leerink increased their price objective on shares of Moderna from $70.00 to $77.00 and gave the company an “underperform” rating in a report on Monday, August 1st. The Goldman Sachs Group increased their price objective on shares of Moderna from $290.00 to $296.00 and gave the company a “buy” rating in a report on Thursday, October 13th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “hold” rating to a “buy” rating and increased their target price for the company from $155.00 to $165.00 in a research note on Wednesday, September 7th. Finally, Argus cut their target price on shares of Moderna from $180.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, September 14th. One analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average price target of $201.00.
In related news, President Stephen Hoge sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 25th. The shares were sold at an average price of $162.75, for a total transaction of $1,627,500.00. Following the transaction, the president now directly owns 1,624,231 shares of the company’s stock, valued at $264,343,595.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Moderna news, CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $168.11, for a total value of $6,724,400.00. Following the completion of the sale, the chief executive officer now directly owns 5,411,946 shares in the company, valued at $909,802,242.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Stephen Hoge sold 10,000 shares of Moderna stock in a transaction that occurred on Monday, July 25th. The shares were sold at an average price of $162.75, for a total transaction of $1,627,500.00. Following the completion of the sale, the president now owns 1,624,231 shares of the company’s stock, valued at $264,343,595.25. The disclosure for this sale can be found here. Insiders have sold 633,048 shares of company stock worth $93,645,982 over the last 90 days. 17.30% of the stock is owned by company insiders.
Hedge Funds Weigh In On Moderna
Institutional investors have recently modified their holdings of the company. AllSquare Wealth Management LLC acquired a new stake in Moderna in the 1st quarter valued at approximately $26,000. Oliver Lagore Vanvalin Investment Group acquired a new stake in Moderna in the 1st quarter valued at approximately $30,000. Reitz Capital Advisors LLC acquired a new stake in Moderna in the 1st quarter valued at approximately $30,000. FourThought Financial LLC grew its holdings in Moderna by 188.5% in the 1st quarter. FourThought Financial LLC now owns 176 shares of the company’s stock valued at $30,000 after buying an additional 115 shares during the last quarter. Finally, Total Clarity Wealth Management Inc. acquired a new stake in Moderna in the 2nd quarter valued at approximately $25,000. Institutional investors own 60.76% of the company’s stock.
Moderna Price Performance
The stock has a market cap of $52.99 billion, a price-to-earnings ratio of 4.11, a price-to-earnings-growth ratio of 0.78 and a beta of 1.70. The stock has a fifty day simple moving average of $137.59 and a 200-day simple moving average of $145.79. The company has a current ratio of 1.99, a quick ratio of 1.71 and a debt-to-equity ratio of 0.04.
Moderna (NASDAQ:MRNA – Get Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 EPS for the quarter, topping analysts’ consensus estimates of $4.50 by $0.74. Moderna had a return on equity of 94.76% and a net margin of 61.12%. The company had revenue of $4.73 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter last year, the company earned $6.46 EPS. The company’s quarterly revenue was up 8.7% on a year-over-year basis. As a group, equities research analysts expect that Moderna, Inc. will post 26.24 EPS for the current year.
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.